annb0t
Top 20
Aurinia Pharmaceuticals AUPH stock was up about 11% on Tuesday after the company announced that the United States Patent and Trademark Office (USPTO) issued a new and refined method-of-use patent for Lupkynis for the treatment of lupus nephritis. The newly issued patent corroborates the unique and proprietary dosing regimen of Auriniaâs currently marketed product, Lupkynis.
In the past year, shares of Aurinia have decreased 10.9% compared with the industryâs 18% fall. Zacks Investment...
>>> Read more: Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent
In the past year, shares of Aurinia have decreased 10.9% compared with the industryâs 18% fall. Zacks Investment...
>>> Read more: Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent
